Recently Featured

Vedana Therapeutics Secures $46 Million to Develop Anti-PACAP Migraine Therapies

June 17, 2026
Vedana Therapeutics emerged from stealth Wednesday with $46 million to support its mission of developing “anti-PACAP” therapies, an increasingly popular strategy for migraine prevention. This funding marks a significant milestone for Vedana, positioning it within a competitive landscape where innovative migraine treatments are in high demand. The anti-PACAP approach targets the peptide involved in migraine…

Altaris to acquire Simulations Plus in $375m all-cash deal

June 17, 2026
Simulations Plus has entered a definitive agreement to be acquired by affiliates of Altaris in an all-cash transaction valued at $375 million. This acquisition marks a significant move in the pharmaceutical industry, as Simulations Plus is known for its innovative software solutions that enhance drug development processes. The deal highlights Altaris’ strategic focus on expanding…

Zai Lab’s zocilurtatug pelitecan secures EMA orphan drug status

June 17, 2026
Zai Lab has achieved a significant milestone with the European Medicines Agency (EMA) granting orphan drug designation (ODD) for zocilurtatug pelitecan (zoci), an investigational antibody-drug conjugate (ADC) targeting DLL3 for the treatment of pulmonary neuroendocrine carcinomas (NECs). This designation is pivotal as it not only underscores the potential of zoci in addressing unmet medical needs…

Relay’s PI3Kα Inhibitor Zovegalisib Achieves Promising Results in Phase 2 Study for Vascular Anomalies

June 16, 2026
Relay Therapeutics has announced that its PI3Kα inhibitor, zovegalisib, has successfully cleared efficacy benchmarks in a Phase 2 clinical trial focused on vascular anomalies, surpassing Wall Street’s expectations. This development marks a significant milestone for Relay, as it broadens the therapeutic applications of zovegalisib beyond its initial focus on breast cancer treatment. The positive data…

Ongoing Cases